Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lotti

Showing results (51-60 of 124) with videos related to

Pageof 13
Sort By:
Digestion|January 1, 1986
Evidence that cholecystokinin octapeptide (CCK-8) acts as a potent, full agonist on gastrin receptors for acid secretion in the isolated mouse stomach: lack of antagonism by the specific CCK antagonist asperlicinV J Lotti, R S Chang, P J Kling, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1992
Cardiac angiotensin receptors: effects of selective angiotensin II receptor antagonists, DUP 753 and PD 121981, in rabbit heartA L Scott, R S Chang, V J Lotti, et al.
Biochemical and Biophysical Research Communications|September 14, 1990
Two angiotensin II binding sites in rat brain revealed using [125I]Sar1, Ile8-angiotensin II and selective nonpeptide antagonistsR S Chang, V J Lotti, T B Chen, et al.
Life Sciences|November 3, 1986
A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonistsV J Lotti, D J Cerino, P J Kling, et al.
Molecular Pharmacology|September 1, 1986
Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptorsR S Chang, V J Lotti, T B Chen, et al.
Life Sciences|February 21, 1983
Increase in brain 125I-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine or ventral tegmental lesionsR S Chang, V J Lotti, G E Martin, et al.
Journal of Biological Regulators and Homeostatic Agents|July 14, 2017
Laser treatment of post-thyroidectomy scarF Borgia, M Vaccaro, L Gasco, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|September 1, 1973
Comparison of centrally mediated hypotensive action of methyldopa and DOPA in catsM L Torchiana, V J Lotti, C M Clark, et al.
Neuroscience Letters|December 12, 1986
Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonistR S Chang, V J Lotti, T B Chen, et al.
Biochemical and Biophysical Research Communications|January 29, 1986
Characterization of [3H]pentagastrin binding in guinea pig gastric glands--an alternative convenient ligand for receptor binding assayR S Chang, V J Lotti, M E Keegan, et al.
Pageof 13

Showing results (51-60 of 124) with videos related to

Sort By:
Pageof 13
Digestion|January 1, 1986
Evidence that cholecystokinin octapeptide (CCK-8) acts as a potent, full agonist on gastrin receptors for acid secretion in the isolated mouse stomach: lack of antagonism by the specific CCK antagonist asperlicinV J Lotti, R S Chang, P J Kling, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1992
Cardiac angiotensin receptors: effects of selective angiotensin II receptor antagonists, DUP 753 and PD 121981, in rabbit heartA L Scott, R S Chang, V J Lotti, et al.
Biochemical and Biophysical Research Communications|September 14, 1990
Two angiotensin II binding sites in rat brain revealed using [125I]Sar1, Ile8-angiotensin II and selective nonpeptide antagonistsR S Chang, V J Lotti, T B Chen, et al.
Life Sciences|November 3, 1986
A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonistsV J Lotti, D J Cerino, P J Kling, et al.
Molecular Pharmacology|September 1, 1986
Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptorsR S Chang, V J Lotti, T B Chen, et al.
Life Sciences|February 21, 1983
Increase in brain 125I-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine or ventral tegmental lesionsR S Chang, V J Lotti, G E Martin, et al.
Journal of Biological Regulators and Homeostatic Agents|July 14, 2017
Laser treatment of post-thyroidectomy scarF Borgia, M Vaccaro, L Gasco, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|September 1, 1973
Comparison of centrally mediated hypotensive action of methyldopa and DOPA in catsM L Torchiana, V J Lotti, C M Clark, et al.
Neuroscience Letters|December 12, 1986
Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonistR S Chang, V J Lotti, T B Chen, et al.
Biochemical and Biophysical Research Communications|January 29, 1986
Characterization of [3H]pentagastrin binding in guinea pig gastric glands--an alternative convenient ligand for receptor binding assayR S Chang, V J Lotti, M E Keegan, et al.
Pageof 13